Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™ - Sleep Apnoea

NCT01557166 · Completed

Last updated 2026-05-28

This clinical trial tested the effect of the medication liraglutide in adults who are obese and have moderate or severe obstructive sleep apnea.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 359 people

Who can join Ages 18–64 · all sexes

Timeline Started 2012-06 · est. completion 2013-06

Where 42 sites · Canada, United States

What this study is testing ClinicalTrials.gov NCT01557166 ↗

Description as written by the study sponsor.

This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.

liraglutide Drug

3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
placebo Drug

Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise

Main thing measured	Change From Baseline in Apnoea-hypopnoea Index (AHI)
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity, Obstructive Sleep Apnoea
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01557166 ↗